Progestogens as a component of menopausal hormone therapy: the right molecule makes the difference

  title={Progestogens as a component of menopausal hormone therapy: the right molecule makes the difference},
  author={J. Stevenson and S. Rozenberg and S. Maffei and C. Egarter and P. Stute and T. R{\"o}mer},
  journal={Drugs in Context},
Optimizing menopausal hormone therapy (MHT) requires an awareness of the benefits and risks associated with the available treatments. This narrative review, which is based on the proceedings of an Advisory Board meeting and supplemented by relevant articles identified in literature searches, examines the role of progestogens in MHT, with the aim of providing practical recommendations for prescribing physicians. Progestogens are an essential component of MHT in menopausal women with a uterus to… Expand
2 Citations

Tables from this paper

Progesterone receptors in normal breast development and breast cancer.
The focus has been put on highlighting the still unresolved topics on hormone treatment involving PR isoforms and breast cancer prognosis by making an overview on PR action in normal and tumor breast. Expand
Gestagengabe in der Menopause: Was sind Unterschiede, Vorteile und Nachteile der einzelnen Präparate?
Frauen mit intaktem Uterus müssen bei der Anwendung eines systemisch wirksamen Östrogens zur Endometriumprotektion ein Gestagen erhalten. Gestagene lassen sich in verschiedene WirkstoffgruppenExpand


Progestogens in menopausal hormone therapy
The choice of progestogen should involve the conscious use of knowledge of its benefits, with a focus on minimizing potential side effects, and there are no direct clinical studies comparing the metabolic effects of different progestogens. Expand
Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.
Differences in chemical structure, metabolism, pharmacokinetics, affinity, potency, and efficacy via steroid receptors, intracellular action, and biological and clinical effects confirm the absence of a class effect of progestogens. Expand
Progestogens in postmenopausal hormone therapy and the risk of breast cancer.
Both the type of the progestogen and the mode of HT administration may have an impact on breast cancer risk, convincing evidence from both clinical trials and epidemiological studies indicates. Expand
Are progestins really necessary as part of a combined HRT regimen?
  • D. Sturdee
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2013
The data are presented but an answer to the posed question remains unclear, as there is particular evidence from the French E3N cohort studies of differential effects of progestins, with progesterone and dydrogesterone additions showing no increase in risk of breast cancer. Expand
Progestogen safety and tolerance in hormonal replacement therapy
Short-term clinical studies, observational, and in animal and in vitro studies indicate that both micronized progesterone and dydrogesterone are the safer progestogens with an acceptable metabolic profile. Expand
Choice of progestogen for endometrial protection in combination with transdermal estradiol in menopausal women
  • A. Mueck, T. Römer
  • Medicine, Biology
  • Hormone molecular biology and clinical investigation
  • 2018
The aim of this review was to summarize data on the endometrial effects of the different progestogens and to provide practical recommendations for the choice of progestogen (type and dosing), with a focus onendometrial protection when using TE, especially when using the novel estradiol (E2) spray. Expand
Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis
Observational studies suggest that in menopausal women, estrogen and progesterone use may be associated with lower breast cancer risk compared to synthetic progestin. Expand
Progesterone, progestins and the breast in menopause treatment
Several non-randomized studies show a lower risk with progesterone and retroprogesterone than with synthetic progestins, and different levels of risk with estrogen-only treatment and combined treatment with estrogen + progestin are shown. Expand
The “newer” progestogens and postmenopausal hormone therapy (HRT)
  • A. Schindler
  • Biology, Medicine
  • The Journal of Steroid Biochemistry and Molecular Biology
  • 2014
Three "newer progestogens" are scrutinized regarding their various actions, in combination with estradiol; the progestogenic include dienogest, drospirenone and nomegestrol acetate. Expand
Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety.
The findings of the retrieved publications confirm that estradiol and dydrogesterone combinations give very effective menopausal symptom relief and prevention of osteoporosis whilst maintaining a good safety profile. Expand